Weiying Liu

Dr. Weiying Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GCGuorong Chen
Guorong Chen
BBBahu Bao
Bahu Bao
YYYucai Ye
Yucai Ye
AHAoyan Hu
Aoyan Hu
JSJingzi Sun
Jingzi Sun
WLWeiying Liu
Weiying Liu
Background: Although the systemic immune-inflammation index (SII) has emerged as a potential prognostic marker in various cancers, its specific role in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy remains insufficiently explored. To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors (ICIs).Method: A comprehensive search was conducted across multiple databases—including PubMed, EMBASE, Cochrane and Web of Science—to identify relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of SII for survival outcomes.Result: Ten studies involving a total of 1,547 patients were included. High systemic immune-inflammation index (SII) was significantly associated with worse overall survival (OS) (HR=1.44, 95% CI=1.21–1.70, p < 0.001; I²=3.8%) and progression-free survival (PFS) (HR=1.44, 95% CI=1.21–1.71, p < 0.001; I²=37.2%). Subgroup analysis indicated that an SII >792 was significantly associated with poorer OS and PFS.Conclusion: High SII is significantly associated with poorer OS and PFS, particularly when SII >792.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024586791, identifier RD42024586791.

29 April 2023 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
WFWenli Fu
Wenli Fu
LLLeping Li
Leping Li
SZSha Zhang
Sha Zhang
SLShengfei Liu
Shengfei Liu
WLWeiying Liu
Weiying Liu

21 March 2022 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
NDNa Dong
Na Dong
WLWeiying Liu
Weiying Liu

6 December 2022 in Immunotherapy
Verified
Journal Article
Closed access
CWChen Wu
Chen Wu
WLWeiying Liu
Weiying Liu
JPJiayuan Pu
Jiayuan Pu
TFTao Feng
Tao Feng
YCYingxuan Chang
Yingxuan Chang
JKJinjun Kai
Jinjun Kai
Checkpoint inhibitor pneumonitis (CIP) is a relatively rare adverse event and a potential cause of death in patients treated with immune checkpoint inhibitors (ICIs). Because the symptoms and signs... Plain language summary We report a patient with advanced lung cancer who experienced shortness of breath induced by immunotherapy. The levels of nitric oxide from the exhaled breath in this case sh...

24 August 2024 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
YYYucai Ye
Yucai Ye
JWJuan Wang
Juan Wang
BBBahu Bao
Bahu Bao
GCGuorong Chen
Guorong Chen
AHAoyan Hu
Aoyan Hu
WLWeiying Liu
Weiying Liu

1 May 2024 in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
Verified
Journal Article
Closed access
LLLeping Li
Leping Li
WFWenli Fu
Wenli Fu
JWJuan Wang
Juan Wang
SZSha Zhang
Sha Zhang
WLWeiying Liu
Weiying Liu
Background: Chronic obstructive pulmonary disease (COPD) is a respiratory illness, with cellular senescence recognized as an essential mechanism driving this chronic lung disease. Salidroside (Sal), a natural compound, is recognized for its anti-aging impacts. Therefore, this study aims to investigate the role and the underlying mechanism of Sal on airway epithelial cell senescence. Methods: In vitro experiments were performed by treating BEAS-2B cells with cigarette smoke extract (CSE), AG490 (Janus kinase 2 (JAK2) inhibitor), or Sal (40 μM, 80 μM, 160 μM). Moreover, senescence-associated β-galactosidase (SA-β-gal) staining and the manifestation of senescence-related genes were used to assess cellular senescence. The mRNA levels of cyclin-dependent kinase inhibitor 2a (p16) and cyclin-dependent kinase inhibitor 1a (p21) were evaluated. Furthermore, Western blot analysis was employed to determine the expression levels of p16, p21, Janus kinase 2 (JAK2), phosphorylated-JAK2 (p-JAK2), signal transducer and activator of transcription 3 (STAT3), and phosphorylated-STAT3 (p-STAT3). Additionally, the cytokine levels associated with the senescence-associated secretory phenotype (SASP) were evaluated utilizing corresponding enzyme-linked immunosorbent assay kits. Results: In vitro, cellular experiments demonstrated that Human bronchial epithelial cells underwent senescence in response to CSE, as evidenced by elevated expression of p16 (p < 0.05) and p21 (p < 0.05), and promotion of senescence-associated secretory phenotype (SASP), as well as up-regulation of JAK2/STAT3 signaling pathway activity. AG490 treatment significantly ameliorated CSE-induced cellular senescence, resulting in down-regulation of the JKA2/STAT3 signaling pathway, alleviation of the senescence molecules p16 (p < 0.05), p21 (p < 0.05), p-JKA2 (p < 0.01) and p-STAT3 (p < 0.05). The inhibitor decreased the secretion of SASP cytokines, and decreased the activity of SA-β-gal. Additionally, Sal reduced p16 (p < 0.01) and p21 (p < 0.05) expression, potentially reversed CSE-induced cellular senescence, and inhibited the JAK2/STAT3 signaling pathway, as well as decreased SASP secretion and SA-β-gal activity. Conclusion: Sal reduces CSE-induced BEAS-2B cellular senescence by inhibiting the JAK2/STAT3 signaling pathway, providing a novel strategy for COPD treatment.